Sovaldi
Drug
Gilead Sciences Inc
Total Payments
$14.8M
Transactions
1,313
Doctors
9
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $116,000 | 11 | 0 |
| 2023 | $140,713 | 32 | 0 |
| 2022 | $397,502 | 130 | 0 |
| 2021 | $533,823 | 145 | 0 |
| 2020 | $1.3M | 196 | 0 |
| 2019 | $2.4M | 190 | 3 |
| 2018 | $2.7M | 243 | 0 |
| 2017 | $7.2M | 366 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.8M | 1,300 | 99.8% |
| Travel and Lodging | $17,826 | 6 | 0.1% |
| Consulting Fee | $5,020 | 2 | 0.0% |
| Food and Beverage | $379.39 | 5 | 0.0% |
Payments by Type
Research
$14.8M
1,300 transactions
General
$23,225
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network. A Longitudinal, Observational Study | Gilead Sciences Inc | $4.8M | 0 |
| REAL-C: Real-world Evidence from the Asia Liver Consortium for HCV | Gilead Sciences, Inc. | $2.5M | 0 |
| A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials | Gilead Sciences, Inc. | $1.3M | 0 |
| HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study | Gilead Sciences, Inc. | $1.3M | 0 |
| REAL-C: Real-world Evidence from the Asia Liver Consortium for HCV | Gilead Sciences Inc | $671,692 | 0 |
| Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego | Gilead Sciences, Inc. | $604,601 | 0 |
| Expand Treatment And Detect, Navigate, Coordinate, Educate To Eliminate (ERADICATE) HCV | Gilead Sciences, Inc. | $599,553 | 0 |
| HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network. A Longitudinal, Observational Study | Gilead Sciences, Inc. | $548,500 | 0 |
| A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials | Gilead Sciences Inc | $362,094 | 0 |
| A Phase 2b Randomized, Open-Label Study of 200mg or 400mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency | Gilead Sciences Inc | $289,684 | 0 |
| A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with GT-2 or GT-3 Chronic HCV Infection | Gilead Sciences Inc | $232,543 | 0 |
| Impact of sofosbuvir-based therapy in liver transplant candidates with hepatitis C virus infection | Gilead Sciences Inc | $176,697 | 0 |
| Impact of sofosbuvir-based therapy in liver transplant candidates with hepatitis C virus infection | Gilead Sciences, Inc. | $157,958 | 0 |
| Determining the Long-term HCV Reinfection Rate of HIV-infected Men after Initial (Primary) HCV Infection in New York City | Gilead Sciences Inc | $136,770 | 0 |
| HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study | Gilead Sciences, Inc. | $118,000 | 0 |
| A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with GT-2 or GT-3 Chronic HCV Infection | Gilead Sciences, Inc. | $115,250 | 0 |
| A Multicenter Study to Evaluate the Efficacy and Safety of Sofosbuvir Based Regimens in Asian-American Adults with Chronic Hepatitis C Infection. | Gilead Sciences Inc | $111,282 | 0 |
| Efficacy and Tolerability of Sofosbuvir, and Impact Upon Clinical Outcomes in HCV Infected Persons in Actual Clinical Setting | Gilead Sciences Inc | $106,491 | 0 |
| Universal Hepatitis C screening: Disease Knowledge, Prevalence, and Linkage to Care Among Patients Presenting to a Large, Publically Funded Urban Emergency Department (ED) | Gilead Sciences Inc | $96,955 | 0 |
| Determining the Long-term HCV Reinfection Rate of HIV-infected Men after Initial (Primary) HCV Infection in New York City | Gilead Sciences, Inc. | $92,542 | 0 |
Top Doctors Receiving Payments for Sovaldi
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $14.8M | 1,300 |
| , M.D | Internal Medicine | Richmond, VA | $6,652 | 2 |
| , M.D | Specialist | San Francisco, CA | $5,917 | 2 |
| , MD | Gastroenterology | Tucson, AZ | $5,257 | 2 |
| , M.D | Hepatology | Boston, MA | $2,946 | 2 |
| , M.D | Pediatrics | Baltimore, MD | $2,100 | 1 |
| , MD | Gastroenterology | Bronx, NY | $125.00 | 1 |
| Tatyana Kushner | Hepatology | New York, NY | $124.99 | 1 |
| , MD | Hepatology | New York, NY | $67.26 | 1 |
| , M.D | Internal Medicine | Flushing, NY | $35.95 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $7.6M
- Gilead Sciences Inc $7.2M
Product Information
- Type Drug
- Total Payments $14.8M
- Total Doctors 9
- Transactions 1,313
About Sovaldi
Sovaldi is a drug associated with $14.8M in payments to 9 healthcare providers, recorded across 1,313 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $116,000 was paid across 11 transactions to 0 doctors.
The most common payment nature for Sovaldi is "Unspecified" ($14.8M, 99.8% of total).
Sovaldi is associated with 20 research studies, including "HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network. A Longitudinal, Observational Study" ($4.8M).